Jan Grimm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4925010/publications.pdf

Version: 2024-02-01

84 papers	7,595 citations	87888 38 h-index	58581 82 g-index
94 all docs	94 docs citations	94 times ranked	11737 citing authors

#	Article	IF	Citations
1	Detection of Shortwave-Infrared Cerenkov Luminescence from Medical Isotopes. Journal of Nuclear Medicine, 2023, 64, 177-182.	5.0	8
2	Biomedical Applications of Lanthanide Nanomaterials, for Imaging, Sensing and Therapy. Nanotheranostics, 2022, 6, 184-194.	5.2	27
3	Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	13
4	Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location. Nature Biomedical Engineering, 2022, 6, 559-568.	22.5	21
5	Optoacoustic Imaging of Glucagon-like Peptide-1 Receptor with a Near-Infrared Exendin-4 Analog. Journal of Nuclear Medicine, 2021, 62, 839-848.	5.0	7
6	Positron Emission Tomography/Computed Tomography with Gallium-68â€“labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model. European Urology Focus, 2021, 7, 472-478.	3.1	4
7	Cerenkov Imaging. , 2021, , 383-395.		1
8	Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer. Journal of Nuclear Medicine, 2021, 62, 1384-1390.	5.0	4
9	Electric boost of MRI contrast for epileptic foci. Nature Biomedical Engineering, 2021, 5, 199-200.	22.5	1
10	Ultrasmall Downconverting Nanoparticle for Enhanced Cerenkov Imaging. Nano Letters, 2021, 21, 4217-4224.	9.1	18
11	A Review of Recent and Emerging Approaches for the Clinical Application of Cerenkov Luminescence Imaging. Frontiers in Physics, 2021, 9, .	2.1	6
12	The ancillary effects of nanoparticles and their implications for nanomedicine. Nature Nanotechnology, 2021, 16, 1180-1194.	31.5	108
13	Positron Lymphography via Intracervical ¹⁸F-FDG Injection for Presurgical Lymphatic Mapping in Cervical and Endometrial Malignancies. Journal of Nuclear Medicine, 2020, 61, 1123-1130.	5.0	8
14	Fluorescence Triggered by Radioactive Î² Decay in Optimized Hyperbolic Cavities. Physical Review Applied, 2020, 14, .	3.8	1
15	Quo Vadis, Molecular Imaging?. Journal of Nuclear Medicine, 2020, 61, 1428-1434.	5.0	9
16	High-resolution optoacoustic imaging of tissue responses to vascular-targeted therapies. Nature Biomedical Engineering, 2020, 4, 286-297.	22.5	92
17	Synthesis of the PET Tracer ¹²⁴I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring. Journal of Nuclear Medicine, 2020, 61, 1845-1850.	5.0	5
18	Photoactivatable Prodrug of Doxazolidine Targeting Exosomes. Journal of Medicinal Chemistry, 2019, 62, 1959-1970.	6.4	12

#	Article	IF	Citations
19	Acid specific dark quencher QC1 pHLIP for multi-spectral optoacoustic diagnoses of breast cancer. Scientific Reports, 2019, 9, 8550.	3.3	16
20	FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nature Nanotechnology, 2019, 14, 616-622.	31.5	199
21	The Present and Future of Optical Imaging Technologies in the Clinic: Diagnosis and Therapy. Topics in Medicinal Chemistry, 2019, , 203-223.	0.8	1
22	High-resolution Cherenkov tomography in vivo. Nature Biomedical Engineering, 2018, 2, 205-206.	22.5	5
23	Nanoparticles as multimodal photon transducers of ionizing radiation. Nature Nanotechnology, 2018, 13, 418-426.	31.5	61
24	Innovations in Nuclear Imaging Instrumentation: Cerenkov Imaging. Seminars in Nuclear Medicine, 2018, 48, 359-366.	4.6	32
25	Dynamic ¹⁸F-FDG PET Lymphography for In Vivo Identification of Lymph Node Metastases in Murine Melanoma. Journal of Nuclear Medicine, 2018, 59, 210-215.	5.0	8
26	Cerenkov-Activated Sticky Tag for In Vivo Fluorescence Imaging. Journal of Nuclear Medicine, 2018, 59, 58-65.	5.0	17
27	Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. Journal of Experimental Medicine, 2018, 215, 159-175.	8.5	121
28	Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Chemical Science, 2018, 9, 5646-5657.	7.4	25
29	Molecular Imaging and Molecular Imaging Technologies. , 2018, , 3-27.		0
30	Design and Synthesis of New Sulfur-Containing Hyperbranched Polymer and Theranostic Nanomaterials for Bimodal Imaging and Treatment of Cancer. ACS Macro Letters, 2017, 6, 235-240.	4.8	25
31	Utilizing the power of Cerenkov light with nanotechnology. Nature Nanotechnology, 2017, 12, 106-117.	31.5	156
32	Advances in the clinical translation of nanotechnology. Current Opinion in Biotechnology, 2017, 46, 66-73.	6.6	30
33	Sonophore labeled RGD: a targeted contrast agent for optoacoustic imaging. Photoacoustics, 2017, 6, 1-8.	7.8	23
34	Near-Infrared Quantum Dot and ⁸⁹Zr Dual-Labeled Nanoparticles for in Vivo Cerenkov Imaging. Bioconjugate Chemistry, 2017, 28, 600-608.	3.6	33
35	Targetable Clinical Nanoparticles for Precision Cancer Therapy Based on Disease-Specific Molecular Inflection Points. Nano Letters, 2017, 17, 7160-7168.	9.1	15
36	Radiation-Responsive Esculin-Derived Molecular Gels as Signal Enhancers for Optical Imaging. ACS Applied Materials & Interfaces, 2017, 9, 43197-43204.	8.0	8

#	Article	IF	Citations
37	PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer. Theranostics, 2017, 7, 2477-2494.	10.0	59
38	Lymph Node Micrometastases and In-Transit Metastases from Melanoma: In Vivo Detection with Multispectral Optoacoustic Imaging in a Mouse Model. Radiology, 2016, 280, 137-150.	7.3	52
39	Optical Imaging of Ionizing Radiation from Clinical Sources. Journal of Nuclear Medicine, 2016, 57, 1661-1666.	5.0	26
40	Nearâ€Infrared Intraoperative Chemiluminescence Imaging. ChemMedChem, 2016, 11, 1978-1982.	3.2	5
41	Stable Radiolabeling of Sulfur-Functionalized Silica Nanoparticles with Copper-64. Nano Letters, 2016, 16, 5601-5604.	9.1	51
42	Nanoparticles and radiotracers: advances toward radionanomedicine. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2016, 8, 872-890.	6.1	51
43	Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist. Journal of Nuclear Medicine, 2015, 56, 805-811.	5.0	39
44	Cerenkov Luminescence Imaging. , 2015, , 107-120.		6
45	Silica Nanoparticles as Substrates for Chelator-free Labeling of Oxophilic Radioisotopes. Nano Letters, 2015, 15, 864-868.	9.1	102
46	Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. European Radiology, 2015, 25, 1294-1302.	4.5	16
47	Therapy from within. Nature Nanotechnology, 2015, 10, 299-300.	31.5	8
48	Multifunctional MRI/PET Nanobeacons Derived from the in Situ Self-Assembly of Translational Polymers and Clinical Cargo through Coalescent Intermolecular Forces. Nano Letters, 2015, 15, 8032-8043.	9.1	25
49	Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nature Communications, 2014, 5, 3097.	12.8	139
50	Molecular Imaging Using Nanoparticle Quenchers of Cerenkov Luminescence. Small, 2014, 10, 3729-3734.	10.0	28
51	Cerenkov Imaging. Advances in Cancer Research, 2014, 124, 213-234.	5.0	59
52	Environment-responsive nanophores for therapy and treatment monitoring via molecular MRI quenching. Nature Communications, 2014, 5, 3384.	12.8	92
53	Nanoparticles for Imaging: Top or Flop?. Radiology, 2014, 273, 10-28.	7.3	195
54	Reply: Human Cerenkov Imaging Using ¹⁸F-FDG. Journal of Nuclear Medicine, 2014, 55, 523.2-524.	5.0	0

#	Article	IF	Citations
55	Clinical Cerenkov Luminescence Imaging of¹⁸F-FDG. Journal of Nuclear Medicine, 2014, 55, 95-98.	5.0	148
56	Dawn of Advanced Molecular Medicine: Nanotechnological Advancements in Cancer Imaging and Therapy. Critical Reviews in Oncogenesis, 2014, 19, 143-176.	0.4	22
57	Quantitative imaging of disease signatures through radioactive decay signal conversion. Nature Medicine, 2013, 19, 1345-1350.	30.7	138
58	Positron Lymphography: Multimodal, High-Resolution, Dynamic Mapping and Resection of Lymph Nodes After Intradermal Injection of ¹⁸F-FDG. Journal of Nuclear Medicine, 2012, 53, 1438-1445.	5.0	55
59	Developing Probes for Molecular Imaging. Medical Radiology, 2012, , 931-940.	0.1	0
60	Enzymatically Activatable Diagnostic Probes. Current Pharmaceutical Biotechnology, 2012, 13, 523-536.	1.6	7
61	Gadolinium-Encapsulating Iron Oxide Nanoprobe as Activatable NMR/MRI Contrast Agent. ACS Nano, 2012, 6, 7281-7294.	14.6	108
62	Cerenkov imaging - a new modality for molecular imaging. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 163-73.	1.0	94
63	Noninvasive cell-tracking methods. Nature Reviews Clinical Oncology, 2011, 8, 677-688.	27.6	439
64	Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions. Molecular Imaging, 2011, 10, 7290.2010.00047.	1.4	53
65	Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions. Molecular Imaging, 2011, 10, 7290.2010.00047.	1.4	44
66	Will Nanotechnology Influence Targeted Cancer Therapy?. Seminars in Radiation Oncology, 2011, 21, 80-87.	2.2	41
67	Clinical applications in molecular imaging. Pediatric Radiology, 2011, 41, 199-207.	2.0	17
68	Targeting the Internal Epitope of Prostate-Specific Membrane Antigen with ⁸⁹Zr-7E11 Immuno-PET. Journal of Nuclear Medicine, 2011, 52, 1608-1615.	5.0	56
69	Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions. Molecular Imaging, 2011, 10, 177-86, 1-3.	1.4	58
70	Cerenkov Luminescence Imaging of Medical Isotopes. Journal of Nuclear Medicine, 2010, 51, 1123-1130.	5.0	279
71	Drug/Dyeâ€Loaded, Multifunctional Iron Oxide Nanoparticles for Combined Targeted Cancer Therapy and Dual Optical/Magnetic Resonance Imaging. Small, 2009, 5, 1862-1868.	10.0	343
72	Integrated Nanosensors to Determine Levels and Functional Activity of Human Telomerase. Neoplasia, 2008, 10, 1066-1072.	5.3	35

#	Article	IF	Citations
73	Noninvasive In Vivo Imaging of Monocyte Trafficking to Atherosclerotic Lesions. Circulation, 2008, 117, 388-395.	1.6	103
74	Imaging in urology â€“ looking forward. Current Opinion in Urology, 2008, 18, 61-64.	1.8	0
75	In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12457-12461.	7.1	113
76	A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Medicine, 2007, 13, 992-997.	30.7	274
77	Restoration of p53 function leads to tumour regression in vivo. Nature, 2007, 445, 661-665.	27.8	1,662
78	An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nature Materials, 2006, 5, 118-122.	27.5	850
79	Metabolic biotinylation of cell surface receptors for in vivo imaging. Nature Methods, 2006, 3, 391-396.	19.0	105
80	Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14404-14409.	7.1	133
81	From Genomics to Clinical Molecular Imaging. Proceedings of the IEEE, 2005, 93, 819-828.	21.3	16
82	Tracking the Recruitment of Diabetogenic CD8+ T-Cells to the Pancreas in Real Time. Diabetes, 2004, 53, 1459-1466.	0.6	107
83	Novel Nanosensors for Rapid Analysis of Telomerase Activity. Cancer Research, 2004, 64, 639-643.	0.9	162
84	Characterization of Ultrasmall, Paramagnetic Magnetite Particles as Superparamagnetic Contrast Agents in MRI. Investigative Radiology, 2000, 35, 553-556.	6.2	12